Talphera (NASDAQ:TLPH) CFO Buys $36,450.00 in Stock

Talphera, Inc. (NASDAQ:TLPH) CFO Raffi Asadorian purchased 45,000 shares of Talphera stock in a transaction on Thursday, February 12th. The shares were acquired at an average cost of $0.81 per share, with a total value of $36,450.00. Following the completion of the transaction, the chief financial officer directly owned 91,256 shares in the company, valued at $73,917.36. The trade was a 97.28% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Talphera Trading Down 3.9%

Shares of TLPH stock traded down $0.03 during trading hours on Friday, hitting $0.78. The company’s stock had a trading volume of 51,448 shares, compared to its average volume of 163,382. The stock has a market cap of $36.20 million, a PE ratio of -2.04 and a beta of 0.46. Talphera, Inc. has a 12-month low of $0.38 and a 12-month high of $1.57. The company has a 50 day moving average of $1.00 and a 200 day moving average of $0.99.

Institutional Investors Weigh In On Talphera

A number of institutional investors have recently modified their holdings of TLPH. AIGH Capital Management LLC acquired a new position in Talphera in the 3rd quarter worth about $3,979,000. Renaissance Technologies LLC increased its position in shares of Talphera by 412.6% in the fourth quarter. Renaissance Technologies LLC now owns 257,380 shares of the company’s stock valued at $293,000 after buying an additional 207,166 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Talphera by 107.0% in the fourth quarter. Geode Capital Management LLC now owns 342,987 shares of the company’s stock valued at $391,000 after buying an additional 177,294 shares in the last quarter. Nantahala Capital Management LLC raised its stake in shares of Talphera by 75.3% during the 3rd quarter. Nantahala Capital Management LLC now owns 3,492,519 shares of the company’s stock worth $3,120,000 after buying an additional 1,500,000 shares during the period. Finally, Cantor Fitzgerald L. P. purchased a new position in shares of Talphera during the 4th quarter valued at approximately $658,000. 37.67% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Talphera in a research note on Wednesday, January 21st. Wall Street Zen raised Talphera to a “hold” rating in a report on Saturday, November 1st. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Talphera currently has an average rating of “Hold” and an average price target of $6.00.

About Talphera

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe.